Molecular mechanisms and therapeutic advances of ferroptosis in radiotherapy resistance of nasopharyngeal carcinoma
Journal of Pharmaceutical Analysis · 2026-10 · 16 (10) · 101576
DOI: 10.1016/j.jpha.2026.101576 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-10. Verfasst von Yue Hu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Radiotherapy is the primary treatment for nasopharyngeal carcinoma (NPC), but radioresistance leads to poor outcomes. Ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, is central to the radiation response in NPC. Resistant cells maintain redox balance primarily via the solute carrier family 7 member 11 (SLC7A11)/glutathione (GSH)/GSH peroxidase 4 (GPX4) axis, which detoxifies lipid peroxides; inhibiting this pathway restores ferroptotic death and radiosensitivity. The ferroptosis suppressor protein 1 (FSP1)/coenzyme Q10 (CoQ10) system provides a parallel antioxidant defense, while acyl-coenzyme A (CoA) synthetase long-chain family member 4 (ACSL4)-mediated incorporation of polyunsaturated fatty acids (PUFAs) promotes ferroptosis susceptibility. Dysregulated iron metabolism, through transferrin (Tf) receptor 1 (TfR1)/divalent metal transporter 1 (DMT1)-mediated uptake and ferritinophagy, elevates the labile iron pool, fueling peroxidation. The hypoxic tumor microenvironment and the Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway further reinforce these defenses, and epstein-barr virus (EBV) infection also suppresses ferroptosis. Translationally, ferroptosis inducers synergize with radiotherapy, and nanodelivery strategies show promise. This review synthesizes these mechanisms and proposes that biomarker-guided approaches to modulate ferroptosis can overcome clinical radioresistance, offering a promising strategy to improve tumor control in NPC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.
Zitieren
APA
Hu, Y., & Zhao, C. (2026). Molecular mechanisms and therapeutic advances of ferroptosis in radiotherapy resistance of nasopharyngeal carcinoma. Journal of Pharmaceutical Analysis, 16(10), 101576. https://doi.org/10.1016/j.jpha.2026.101576
Vancouver
Hu Y, Zhao C. Molecular mechanisms and therapeutic advances of ferroptosis in radiotherapy resistance of nasopharyngeal carcinoma. Journal of Pharmaceutical Analysis. 2026;16(10):101576. doi:10.1016/j.jpha.2026.101576
BibTeX
@article{Hu2026,
author = {Hu, Yue and Zhao, Chen},
title = {Molecular mechanisms and therapeutic advances of ferroptosis in radiotherapy resistance of nasopharyngeal carcinoma},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
volume = {16},
number = {10},
pages = {101576},
doi = {10.1016/j.jpha.2026.101576}
}
EUVIMED